VIDEO: Phase 3 trial shows improvement in survival for subset of men with prostate cancer
In this video, Alicia Morgans, MD, discusses the PEACE-1 phase 3 trial that found adding abiraterone to androgen deprivation therapy plus docetaxel improves radiographic PFS and OS in men with metastatic castration-sensitive prostate cancer.
"What [Fizazi] and the team found is that indeed the triplet of [androgen deprevation therapy] plus docetaxel plus abiraterone is associated with an improvement in overall survival, in addition to the radiographic progression free survival that he already reported in patients as compared to [androgen deprevation therapy] plus docetaxel alone,” Morgans, an associate professor of medicine (hematology and oncology) at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine in Chicago, said.
Researchers are still working to discover if treating the primary tumor directly with radiation will help improve patient survival.
"…as Dr. Fizazi noted, that data remains immature because we do expect the benefit to be most pronounced among patients who have low-volume disease," Morgans said.
Collapse
K. Fizazi, et al. Abstract LBA5_PR. Presented at ESMO Congress 2021; September 16-21, 2021 (virtual meeting).